Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > This gives me less and less and less confidence

<< Previous

Bullboard Posts

Next >>

Comment by polygraph46on Feb 07, 2021 5:46pm

168 Views

Post# 32497009

RE:RE:RE:RE:RE:RE:RE:This gives me less and less and less confidence

Captain:

Looks like the've got academic angelica on board and sipping the Cool Aid over at the Conclave

as well. Please know Captain, that it's exceeding difficult to challenge the misguided. Her gutteral

response with the words "by the way have you done 1% of what he(Salsman) has done" says it

all . kudos to her.......for trying to make a silk purse out of a SOW'S ear. Waiting for the next

chapter of Fluffy the Dog............pg46

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario